Congress Asks FDA for More Information on Aduhelm Approval

Congress Asks FDA for More Information on Aduhelm Approval

305397

Congress Asks FDA for More Information on Aduhelm Approval

Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the agency’s controversial decision to grant accelerated approval to Biogen‘s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. U.S. Rep. Frank Pallone, Jr., chair of the House Committee on Energy and Commerce, and U.S. Rep. Carolyn B. Maloney, chair of the Committee on Oversight and Reform, wrote in a letter to acting FDA commissioner Janet Woodcock,…

You must be logged in to read/download the full post.